Repligen（1RGEN）株式概要リプリジェン・コーポレーションはライフサイエンス企業であり、北米、欧州、アジア太平洋地域、および国際的にバイオプロセス技術とシステムを開発、商業化している。 詳細1RGEN ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長4/6過去の実績2/6財務の健全性5/6配当金0/6報酬当社が推定した公正価値より3.5%で取引されている 収益は年間30.46%増加すると予測されています 今年は黒字化を達成 リスク分析Italian市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去3か月間に大規模なインサイダー売却が発生 すべてのリスクチェックを見る1RGEN Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€127.6521.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-23m1b2016201920222025202620282031Revenue US$1.4bEarnings US$96.0mAdvancedSet Fair ValueView all narrativesRepligen Corporation 競合他社Fine Foods & Pharmaceuticals N.T.MSymbol: BIT:FFMarket cap: €208.4mRecordati Industria Chimica e FarmaceuticaSymbol: BIT:RECMarket cap: €10.5bQiagenSymbol: NYSE:QGENMarket cap: US$8.1bBio-Rad LaboratoriesSymbol: NYSE:BIOMarket cap: US$8.0b価格と性能株価の高値、安値、推移の概要Repligen過去の株価現在の株価US$127.6552週高値US$139.3552週安値US$99.56ベータ1.081ヶ月の変化29.96%3ヶ月変化29.86%1年変化20.08%3年間の変化n/a5年間の変化n/aIPOからの変化1.23%最新ニュースBuy Or Sell Opportunity • Jun 06Now 22% undervaluedOver the last 90 days, the stock has risen 3.3% to €106. The fair value is estimated to be €136, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.お知らせ • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.お知らせ • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026お知らせ • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.お知らせ • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.お知らせ • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026最新情報をもっと見るRecent updatesBuy Or Sell Opportunity • Jun 06Now 22% undervaluedOver the last 90 days, the stock has risen 3.3% to €106. The fair value is estimated to be €136, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.お知らせ • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.お知らせ • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026お知らせ • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.お知らせ • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.お知らせ • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026お知らせ • Jan 07Repligen Corporation Announces Executive Changes, Effective March 13, 2026On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.お知らせ • Dec 17Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsRepligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.Buy Or Sell Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.お知らせ • Oct 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share.お知らせ • Oct 15Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025お知らせ • Jul 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share.お知らせ • Jul 17Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025株主還元1RGENIT Life SciencesIT 市場7D2.3%6.9%-2.7%1Y20.1%-6.3%23.3%株主還元を見る業界別リターン: 1RGEN過去 1 年間で-6.3 % の収益を上げたItalian Life Sciences業界を上回りました。リターン対市場: 1RGENは、過去 1 年間で23.3 % のリターンを上げたItalian市場を下回りました。価格変動Is 1RGEN's price volatile compared to industry and market?1RGEN volatility1RGEN Average Weekly Movement10.6%Life Sciences Industry Average Movement6.5%Market Average Movement4.8%10% most volatile stocks in IT Market8.6%10% least volatile stocks in IT Market3.0%安定した株価: 1RGENの株価は、 Italian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 1RGENの weekly volatility ( 11% ) は過去 1 年間安定していますが、依然としてItalianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19812,000Olivier Loeillotwww.repligen.comリプリジェン・コーポレーションはライフサイエンス企業で、北米、欧州、アジア太平洋地域、および国際的にバイオプロセス技術とシステムの開発・商業化を行う。プロテインAアフィニティークロマトグラフィーレジンの結合成分であるプロテインAリガンド、細胞培養成長因子製品を提供。また、生物製剤の精製に使用されるOPUSプレパックドクロマトグラフィーカラムや、高スループットプロセス開発スクリーニング、ウイルスクリアランス検証試験、クロマトグラフィープロセスのスケールダウンバリデーションに使用されるOPUSスモールスケールカラムなどのクロマトグラフィ製品、ELISAテストキットも提供している。さらに、上流の灌流や細胞培養プロセスで使用されるろ過装置であるXCell ATF Cell Retention Systems、下流の生物学的製剤の濃縮、緩衝液交換、製剤化プロセスで使用されるTangenX flat sheet cassettes、KrosFlo tangential flow filtration and tangential flow depth filtration systems、ProConnex TFDF flow pathsなどのろ過製品を提供している。さらに、SoloVPE、FlowVPE、FlowVPXブランドの勾配分光システムなどのプロセス分析製品も提供している。同社はライフサイエンス、バイオ医薬品、診断薬会社、研究室研究者、製造受託機関向けに製品を販売している。Repligen CorporationはNavigo Proteins GmbHと複数のアフィニティーリガンドの開発に関する共同研究契約を結んでいる。1981年に設立され、マサチューセッツ州ウォルサムに本社を置く。もっと見るRepligen Corporation 基礎のまとめRepligen の収益と売上を時価総額と比較するとどうか。1RGEN 基礎統計学時価総額€7.19b収益（TTM）€45.13m売上高(TTM)€670.29m161.3xPER（株価収益率10.9xP/Sレシオ1RGEN は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1RGEN 損益計算書（TTM）収益US$763.34m売上原価US$357.71m売上総利益US$405.63mその他の費用US$354.23m収益US$51.40m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）0.91グロス・マージン53.14%純利益率6.73%有利子負債／自己資本比率26.0%1RGEN の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/26 18:18終値2026/06/26 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Repligen Corporation 21 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。30 アナリスト機関Luke SergottBarclaysRobert WassermanBenchmark CompanyHugo SolvetBNP Paribas27 その他のアナリストを表示
Buy Or Sell Opportunity • Jun 06Now 22% undervaluedOver the last 90 days, the stock has risen 3.3% to €106. The fair value is estimated to be €136, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.
お知らせ • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.
お知らせ • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
お知らせ • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.
お知らせ • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.
お知らせ • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026
Buy Or Sell Opportunity • Jun 06Now 22% undervaluedOver the last 90 days, the stock has risen 3.3% to €106. The fair value is estimated to be €136, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 30% per annum over the same time period.
お知らせ • May 07An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million.An undisclosed buyer acquired SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026. A cash consideration of $4.4 million will be paid by the buyer. As part of consideration, $4.4 million is paid towards common equity of SA Polymem. For the period ending December 31, 2025, SA Polymem reported total revenue of $7 million. An undisclosed buyer completed the acquisition of SA Polymem from Repligen Corporation (NasdaqGS:RGEN) for approximately $4.4 million on March 30, 2026.
お知らせ • Apr 22Repligen Corporation to Report Q1, 2026 Results on May 05, 2026Repligen Corporation announced that they will report Q1, 2026 results Pre-Market on May 05, 2026
お知らせ • Apr 03Repligen Corporation, Annual General Meeting, May 14, 2026Repligen Corporation, Annual General Meeting, May 14, 2026.
お知らせ • Feb 24Repligen Corporation Provides Earnings Guidance for the Full Year 2026Repligen Corporation provided earnings guidance for the full year 2026. For the year, the company expects total reported revenue of $810 million to $840 million, Gross Margin of 53.6% to 54.1%, Income from Operations of $122 million to $130 million, Operating Margin of 15.1% to 15.5%, net income of $109 million to $114 million and Earnings per share - Diluted of $1.93 per share to $2.01 per share.
お知らせ • Feb 10Repligen Corporation to Report Q4, 2025 Results on Feb 24, 2026Repligen Corporation announced that they will report Q4, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 24, 2026
お知らせ • Jan 07Repligen Corporation Announces Executive Changes, Effective March 13, 2026On January 6, 2026, Repligen Corporation announced that the Board of Directors has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. Dr. Madaus will succeed Tony J. Hunt, who is currently serving as the Executive Chair of the Board, following his previously announced March 2026 retirement, which shall be on the Effective Date, at which time Mr. Hunt will retire as a member of the Board. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027. Martin D. Madaus, D.V.M., Ph.D., has served as a director of Repligen since February 2023. Dr. Madaus has 36 years of industry experience, including five years as Chairman, President and CEO of Millipore Corporation, where he was integral to the company’s transformation into a life science leader, and its acquisition by Merck KGaA in 2010. Dr. Madaus serves on the boards of Azenta Inc. and Hologic Inc. He holds a D.V.M. from the University of Munich in Germany and a Ph.D. from the University of Veterinary Medicine of Hanover in Germany.
お知らせ • Dec 17Repligen Introduces Next-Generation Chromatography Resins to Advance New Modality WorkflowsRepligen Corporation announced the launch of three new high-performance chromatography resins: AVIPure®? HiPer™? AAV9 and AVIPure®? Hi Per™? AAV8 affinity resins, along with HiPer™? QA anion-exchange resin, expanding the company's growing proteins portfolio and reinforcing its commitment to innovation in next-generation bioprocessing. Built on the Tantti™? DuloCore™? base bead technology, the new convective HiPer resins deliver the differentiated performance required for new modalities, including viral vectors. These solutions are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, ultimately enabling faster, more reliable paths to market. As momentum continues across new modalities, Repligen remains focused on providing customers with the cutting-edge tools they need. These new resins extend the company's leadership in process productivity and strengthen its portfolio ahead of broader chromatography resin launches anticipated in 2026.
Buy Or Sell Opportunity • Nov 06Now 21% undervaluedOver the last 90 days, the stock has risen 22% to €123. The fair value is estimated to be €155, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 6.2% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 45% per annum over the same time period.
Reported Earnings • Oct 29Third quarter 2025 earnings released: EPS: US$0.27 (vs US$0.012 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.27 (up from US$0.012 loss in 3Q 2024). Revenue: US$188.8m (up 22% from 3Q 2024). Net income: US$14.9m (up US$15.6m from 3Q 2024). Profit margin: 7.9% (up from net loss in 3Q 2024). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe.
お知らせ • Oct 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year, the total reported revenue of $729 million to $737 million, Income from Operations of $50 million to $52 million, net income of $46.5 million to $48 million and Earnings per share - Diluted of $0.82 per share to $0.85 per share.
お知らせ • Oct 15Repligen Corporation to Report Q3, 2025 Results on Oct 28, 2025Repligen Corporation announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Oct 28, 2025
お知らせ • Jul 29Repligen Corporation Updates Financial Guidance for the Full Year 2025Repligen Corporation updated financial guidance for the full year 2025. For the year total reported revenue of $715 million to $735 million, Income from Operations of $51 million- $56 million, net income of $48 million - $51.5 million and Earnings per share - Diluted of $0.85 per share - $0.92 per share.
お知らせ • Jul 17Repligen Corporation to Report Q2, 2025 Results on Jul 29, 2025Repligen Corporation announced that they will report Q2, 2025 results at 9:30 AM, US Eastern Standard Time on Jul 29, 2025
